#ASH17: Blue­bird touts ear­ly signs that its new-and-im­proved sick­le cell gene ther­a­py is work­ing

Blue­bird bio $BLUE says they’ve been able to gath­er ev­i­dence to help prove that their new-and-im­proved ap­proach to mak­ing a gene ther­a­py for sick­le cell dis­ease has the po­ten­tial to be a con­sis­tent­ly ef­fec­tive once-and-done ther­a­py.

Fol­low­ing up on some dis­ap­point­ing ev­i­dence of in­con­sis­ten­cy among the first small group of pa­tients treat­ed with Lenti­Glo­bin, blue­bird’s team went back to the draw­ing board to whip up a new ap­proach to man­u­fac­tur­ing that they be­lieved would over­come their ini­tial set­back.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER